Skip to main content

Familial Cancer

Ausgabe 3/2018

Inhalt (20 Artikel)

Open Access Letter to the Editor

Increased access to TP53 analysis through breast cancer multi-gene panels: clinical considerations

Jacopo Azzollini, Milena Mariani, Bernard Peissel, Siranoush Manoukian

Original Article

Family history influences the tumor characteristics and prognosis of breast cancers developing during postmenopausal hormone therapy

Rainer Fagerholm, Maria Faltinova, Kirsi Aaltonen, Kristiina Aittomäki, Päivi Heikkilä, Mervi Halttunen-Nieminen, Heli Nevanlinna, Carl Blomqvist

Original Article

Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations

Stephanie Kearton, Karen Wills, Michael Bunting, Penny Blomfield, Paul A. James, Jo Burke

Open Access Original Article

Targeted massively parallel sequencing characterises the mutation spectrum of PALB2 in breast and ovarian cancer cases from Poland and Ukraine

Aleksander Myszka, Tu Nguyen-Dumont, Pawel Karpinski, Maria M. Sasiadek, Hayane Akopyan, Fleur Hammet, Helen Tsimiklis, Daniel J. Park, Bernard J. Pope, Ryszard Slezak, Nataliya Kitsera, Aleksandra Siekierzynska, Melissa C. Southey

Original Article

Information and support needs of young women regarding breast cancer risk and genetic testing: adapting effective interventions for a novel population

Suzanne C. O’Neill, Chalanda Evans, Rebekah J. Hamilton, Beth N. Peshkin, Claudine Isaacs, Sue Friedman, Kenneth P. Tercyak

Open Access Original Article

Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers

A. Goverde, M. C. W. Spaander, D. Nieboer, A. M. W. van den Ouweland, W. N. M. Dinjens, H. J. Dubbink, C. J. Tops, S. W. ten Broeke, M. J. Bruno, R. M. W. Hofstra, E. W. Steyerberg, A. Wagner

Open Access Original Article

Evaluation of an online family history tool for identifying hereditary and familial colorectal cancer

F. G. J. Kallenberg, C. M. Aalfs, F. O. The, C. A. Wientjes, A. C. Depla, M. W. Mundt, P. M. M. Bossuyt, E. Dekker

Short Communication

Ectopic, retroperitoneal adrenocortical carcinoma in the setting of Lynch syndrome

Jesse P. Wright, Kathleen W. Montgomery, Joshua Tierney, Jill Gilbert, Carmen C. Solórzano, Kamran Idrees

Original Article

Screening for germline mutations in mismatch repair genes in patients with Lynch syndrome by next generation sequencing

Barbara Luísa Soares, Ayslan Castro Brant, Renan Gomes, Tatiane Pastor, Naye Balzan Schneider, Ândrea Ribeiro-dos-Santos, Paulo Pimentel de Assumpção, Maria Isabel W. Achatz, Patrícia Ashton-Prolla, Miguel Angelo Martins Moreira

Original Article

Universal determination of microsatellite instability using BAT26 as a single marker in an Argentine colorectal cancer cohort

María Laura González, Natalia Causada-Calo, Juan Pablo Santino, Mev Dominguez-Valentin, Fabiana Alejandra Ferro, Inés Sammartino, Pablo Germán Kalfayan, Maria Alicia Verzura, Tamara Alejandra Piñero, Andrea Romina Cajal, Walter Pavicic, Carlos Vaccaro

Review

Phenotypic and genotypic heterogeneity of Lynch syndrome: a complex diagnostic challenge

Henry T. Lynch, Stephen Lanspa, Trudy Shaw, Murray Joseph Casey, Marc Rendell, Mark Stacey, Theresa Townley, Carrie Snyder, Megan Hitchins, Joan Bailey-Wilson

Open Access Short Communication

Excluding Lynch syndrome in a female patient with metachronous DNA mismatch repair deficient colon- and ovarian cancer

Stijn Crobach, Anne M. L. Jansen, Marjolein J. L. Ligtenberg, Marije Koopmans, Maartje Nielsen, Frederik J. Hes, Juul T. Wijnen, Winand N. M. Dinjens, Tom van Wezel, Hans Morreau

Review

An exploration of genotype-phenotype link between Peutz-Jeghers syndrome and STK11: a review

Julian Daniell, John-Paul Plazzer, Anuradha Perera, Finlay Macrae

Letter to the Editor

Germline mutations in lung cancer and personalized medicine

Francesco Cetta, Alessandra Renieri, Elisa Frullanti

Short Communication

Penetrance of a rare familial mutation predisposing to papillary thyroid cancer

Donika Saporito, Pamela Brock, Heather Hampel, Jennifer Sipos, Soledad Fernandez, Sandya Liyanarachchi, Albert de la Chapelle, Rebecca Nagy

Open Access Original Article

Germline variant in MSX1 identified in a Dutch family with clustering of Barrett’s esophagus and esophageal adenocarcinoma

A. M. J. van Nistelrooij, R. van Marion, W. F. J. van Ijcken, A. de Klein, A. Wagner, K. Biermann, M. C. W. Spaander, J. J. B. van Lanschot, W. N. M. Dinjens, B. P. L. Wijnhoven

Original Article

Genotype phenotype correlation in Asian Indian von Hippel–Lindau (VHL) syndrome patients with pheochromocytoma/paraganglioma

Nilesh Lomte, Sanjeet Kumar, Vijaya Sarathi, Reshma Pandit, Manjunath Goroshi, Swati Jadhav, Anurag R. Lila, Tushar Bandgar, Nalini S. Shah

Original Article

Cost-effectiveness evaluation of pre-counseling telephone interviews before face-to-face genetic counseling in cancer genetics

Gaëlle Collet, Nathalie Parodi, Kevin Cassinari, Zoe Neviere, Fanny Cohen, Céline Gasnier, Afane Brahimi, François Lecoquierre, Jean-Christophe Thery, Isabelle Tennevet, Elodie Lacaze, Pascaline Berthet, Thierry Frebourg

Review

Association between miR-146a rs2910164 polymorphism and specific cancer susceptibility: an updated meta-analysis

Xia Hao, Lingzi Xia, Ruoyi Qu, Xianglin Yang, Min Jiang, Baosen Zhou

Correction

Corrections to: Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries

Anne Brédart, Jean‑Luc Kop, Antonis C. Antoniou, Alex P. Cunningham, Antoine De Pauw, Marc Tischkowitz, Hans Ehrencrona, Sylvie Dolbeault, Léonore Robieux, Kerstin Rhiem, Douglas F. Easton, Peter Devilee, Dominique Stoppa‑Lyonnet, Rita Schmutlzer

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.